Are There New Advances in the Pharmacotherapy of Autism Spectrum Disorders?

Overview

Journal World Psychiatry

Specialty Psychiatry

Date 2017 Jan 28

PMID 28127936

Citations 5

Authors

Eric Hollander

Genoveva Uzunova

Affiliations

Soon will be listed here.

Citing Articles

Effects of Walnut and Pumpkin on Selective Neurophenotypes of Autism Spectrum Disorders: A Case Study.

El-Ansary A, Al-Ayadhi L Nutrients. 2023; 15(21).

PMID: 37960217 PMC: 10647375. DOI: 10.3390/nu15214564.

Genetics of glutamate and its receptors in autism spectrum disorder.

Nisar S, Bhat A, Masoodi T, Hashem S, Akhtar S, Ali T Mol Psychiatry. 2022; 27(5):2380-2392.

PMID: 35296811 PMC: 9135628. DOI: 10.1038/s41380-022-01506-w.

Interventions on Microbiota: Where Do We Stand on a Gut-Brain Link in Autism? A Systematic Review.

Prosperi M, Santocchi E, Guiducci L, Frinzi J, Morales M, Tancredi R Nutrients. 2022; 14(3).

PMID: 35276821 PMC: 8839651. DOI: 10.3390/nu14030462.

Utilizing Genomically Targeted Molecular Data to Improve Patient-Specific Outcomes in Autism Spectrum Disorder.

Hausman-Cohen S, LaValley W, Way H, Gutierrez E, Reeder J Int J Mol Sci. 2022; 23(4).

PMID: 35216282 PMC: 8879068. DOI: 10.3390/ijms23042167.

Effects of Probiotic Supplementation on Gastrointestinal, Sensory and Core Symptoms in Autism Spectrum Disorders: A Randomized Controlled Trial.

Santocchi E, Guiducci L, Prosperi M, Calderoni S, Gaggini M, Apicella F Front Psychiatry. 2020; 11:550593.

PMID: 33101079 PMC: 7546872. DOI: 10.3389/fpsyt.2020.550593.

References

Costales J, Kolevzon A . The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev. 2016; 63:207-22. PMC: 4790729. DOI: 10.1016/j.neubiorev.2016.01.001. View

Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G . The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl). 2013; 231(6):1237-50. PMC: 3932172. DOI: 10.1007/s00213-013-3289-0. View

Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria C, Aronowitz B . Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology. 2002; 28(1):193-8. DOI: 10.1038/sj.npp.1300021. View

Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S . Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012; 3(1):16. PMC: 3539865. DOI: 10.1186/2040-2392-3-16. View

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor B, Ferretti C . A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2011; 169(3):292-9. DOI: 10.1176/appi.ajp.2011.10050764. View

Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S . A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2004; 30(3):582-9. DOI: 10.1038/sj.npp.1300627. View

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J . Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2009; 35(4):990-8. PMC: 2846602. DOI: 10.1038/npp.2009.202. View

Uzunova G, Pallanti S, Hollander E . Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World J Biol Psychiatry. 2015; 17(3):174-86. DOI: 10.3109/15622975.2015.1085597. View

Erickson C, Veenstra-VanderWeele J, Melmed R, McCracken J, Ginsberg L, Sikich L . STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2013; 44(4):958-64. DOI: 10.1007/s10803-013-1963-z. View

10.

Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L . Oxytocin increases retention of social cognition in autism. Biol Psychiatry. 2006; 61(4):498-503. DOI: 10.1016/j.biopsych.2006.05.030. View